PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.
Evidence
MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer
PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. AUTHORS: Grant K.A., Apffelstaedt J.P., Wright C.A., Myburgh E., Pienaar R., De Klerk M., Kotze M.J. SUMMARY: The 70-gene profile classifies approximately 40% of early-stage breast cancer patients as low-risk compared with 15% using conventional criteria. In comparison, more than Read More
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retèl V.P., Groothuis-Oudshoorn C.G., Aaronson N.K., Brewer N.T., Rutgers E.J., van Harten W.H. SUMMARY: Based on MINDACT: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Read more: Retèl Read More
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in Read More
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chéreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(®) and MammaPrint. Studies of both tests provided evidence Read More
A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study
PUBLICATION: Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082. Epub 2013 Mar 4. AUTHORS: Drukker C.A., Bueno-de-Mesquita J.M., Retèl V.P., van Harten W.H., van Tinteren H., Wesseling J., Roumen R.M., Knauer M., van't Veer L.J., Sonke G.S., Rutgers E.J., van de Vijver M.J., Linn S.C. SUMMARY: A prospective community based Read More
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
PUBLICATION: Scientifica (Cairo). 2012; 2012: 942507. Published online 2012 Dec 31. doi: 10.6064/2012/942507. AUTHORS: C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, and Sheldon Feldman SUMMARY: This study indicates that using MP/TP assay is feasible in a tertiary care center but there may be utility Read More
Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer
PUBLICATION: The Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun 26. AUTHORS: Kok M., Koornstra R.H., Mook S., Hauptmann M., Fles R., Jansen M.P., Berns E.M., Linn S.C., Van 't Veer L.J. SUMMARY: In the series analysed, the 70-gene signature was mainly a prognostic factor, while ER and PR levels Read More
